^
    Apply
    APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330)
    Phase 1
    Yale University
    Completed
    Last update posted :
    07/03/2024
    Initiation :
    06/09/2018
    Primary completion :
    01/05/2022
    Completion :
    05/15/2024
    PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG
    |
    EGFR mutation • EGFR T790M • ALK rearrangement
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)
    Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer (NCT04331067)
    Phase 1/2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    11/19/2020
    Primary completion :
    03/20/2023
    Completion :
    05/31/2026
    HER-2 • ER
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • carboplatin • paclitaxel • cabiralizumab (BMS-986227)
    Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (NCT03927105)
    Phase 2
    University of Michigan Rogel Cancer Center
    Completed
    Last update posted :
    03/18/2024
    Initiation :
    04/25/2019
    Primary completion :
    11/01/2019
    Completion :
    07/06/2023
    TNFRSF8
    |
    TNFRSF8 positive
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227)
    Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer (C4-MOSART) (NCT03431948)
    Phase 1
    University of Chicago
    Completed
    Last update posted :
    02/16/2023
    Initiation :
    03/15/2018
    Primary completion :
    02/29/2020
    Completion :
    04/11/2022
    EGFR
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227) • urelumab (BMS-663513)